Number of suitable clients: CDEC talked about the uncertainty in the quantity of sufferers with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who will be labeled as obtaining gentle or moderate disease can have a intense bleeding p… Read More